ABCG2 Overexpression Contributes to Pevonedistat Resistance

MLN4924 (pevonedistat) is a first-in-class NEDD8-activating enzyme (NAE) inhibitor in clinical trials for the treatment of solid tumors and hematologic malignancies. Despite the promising activity of MLN4924 observed in early trials, drug resistance has been noted in some patients. Identifying the u...

Descripción completa

Detalles Bibliográficos
Autores principales: Kathawala, Rishil J., Espitia, Claudia M., Jones, Trace M., Islam, Shariful, Gupta, Pranav, Zhang, Yun-Kai, Chen, Zhe-Sheng, Carew, Jennifer S., Nawrocki, Steffan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072604/
https://www.ncbi.nlm.nih.gov/pubmed/32059437
http://dx.doi.org/10.3390/cancers12020429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072604/
https://www.ncbi.nlm.nih.gov/pubmed/32059437
http://dx.doi.org/10.3390/cancers12020429

Ejemplares similares